Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 33, 2018 - Issue 1
Submit an article Journal homepage
2,510
Views
41
CrossRef citations to date
0
Altmetric
Research Paper

Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold

Heba S. A. ElzahabiDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt; View further author information
,
Eman S. NossierDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt; View further author information
,
Nagy M. KhalifaDrug Exploration & Development Chair (DEDC), Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-9019-925XView further author information
ORCID Icon,
Rania A. AlasfouryDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt; View further author information
&
May A. El-ManawatyDepartment of Pharmacognosy, Pharmaceutical Science Division, National Research Centre, Cairo, EgyptView further author information
Pages 546-557 | Received 01 Jan 2018, Accepted 05 Feb 2018, Published online: 27 Feb 2018

References

  • Wu H-C, Chang D-K, Huang CT. Targeted therapy for cancer. J Cancer Mol 2006;2:57–66.
  • Varmus H. The new era in cancer research. Science 2006;312:1162–5.
  • Zheng LW, Li Y, Ge D, et al. Synthesis of novel oxime-containing pyrazole derivatives and discovery of regulators for apoptosis and autophagy in A549 lung cancer cells. Bioorg Med Chem Lett 2010;20:4766–70.
  • Eckford PDW, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009;109:2989–3011.
  • Lage L. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008;65:3145–67.
  • Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Cancer Treat Rev 2003;29:297–307.
  • Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nature Reviews/Drug Discovery 2006;5:219–34.
  • Chorawala MR, Oza PM, Shah GB. Mechanisms of anticancer drugs resistance: an overview. IJPSDR 2012;4:1–9.
  • Denny WA. DNA minor groove alkylating agents. Exp Opin Ther Patents 2000;10:459–74.
  • Denny WA, Atwell GJ, Baguley BC, Wakelin LPG. Potential antitumor agents. Synthesis and antitumor activity of new classes of diacridines: importance of linker chain rigidity for DNA binding kinetics and biological activity. J Med Chem 1985;28:1568–74.
  • Patrick GL. An introduction to medicinal chemistry. 3rd ed. New York: Oxford University Press Inc.; 2005: 489–553.
  • Abou-Seri FSM, Abdel-Aziz HA, Abbas SE, et al. Synthesis and antitumor activity of pyrido[2,3-d]pyrimidine and pyrido[2,3-d] [1,2,4]triazolo[4,3-a]pyrimidine derivatives that induce apoptosis through G1 cell-cycle arrest. Eur J Med Chem 2014;83:155–66.
  • Rodriguez R, Meuth M. Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell 2006;17:402–12.
  • Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
  • Nossier ES, El-Hallouty SM, Zaki ER. Synthesis, anticancer evaluation and molecular modeling of some substituted thiazolidinonyl and thiazolyl pyrazole derivatives. Int J Pharm Sci 2015;7:353–9.
  • El-serwy WS, Mohamed NA, El-serwy WS, et al. Synthesis, molecular modeling studies and biological evaluation of novel pyrazole as antitumor and EGFR inhibitors. Int J Pharm Tech 2016;8:25192–209.
  • Molecular Operating Environment (MOE), 2008.10; Chemical Computing Group ULC, 1010 Sherbrooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7.
  • Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain, alone and in complex with a 4 anilinoquinazoline inhibitor. J BioChem 2002;277:46265–72.
  • Traxler P, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther 1999;82:195–206.
  • Gahmen US, HouKim S. Structure basis for CDK6 activation by a virus encoded cyclin. Nature Struc Bio 2002;9:177–81.
  • Tadesse S, Yu M, Kumarasiri M, et al. Targeting CDK6 in cancer: state of the art and new insights. Cell Cycle 2015;14:3220–30.
  • Abdallaha MA, Gomha SM, Morad MA, Elaasser MM. Synthesis of pyridotriazolopyrimidines as antitumor agents. J Het Chem 2016;24:1242–51.
  • Farghaly TA, Hassaneen HME. Synthesis of pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5-ones as potential antimicrobial agents. Arch Pharm Res 2013;36:564–72.
  • El-Nassan HB. Synthesis and antitumor activity of novel pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5-one derivatives. Eur Med Chem 2011;46:2031–6.
  • El-Gazzar AB, Gaafar AM, Aly AS. Synthesis of some new thiazolo[3,2-a]pyrido[2,3-d]pyrimidinones and Isoxazolo[5′,4′:4,5]thiazolo[3,2-a]pyrido[2,3-d]pyrimidinone. Phosphorus Sulfur Silicon 2002;177:45–58.
  • Ismail MMF, Rateb HS, Hussein MM. Synthesis and docking studies of novel benzopyran-2-ones with anticancer activity. Eur J Med Chem 2010;45:3950–9.
  • Conconi MT, Marzaro G, Urbani L, et al. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties. Eur J Med Chem 2013;67:373–83.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.